We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

PTC Therapeutics Inc (PTCT) Common Stock USD0.001

Sell:$28.30 Buy:$28.31 Change: $0.39 (1.40%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $0.39 (1.40%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
Change: $0.39 (1.40%)
Market closed |  Prices as at close on 27 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PTC Therapeutics, Inc. is a science-driven, global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Its portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It also offers Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, and Evrysdi, a treatment for spinal muscular atrophy (SMA). Its splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease (HD).

Contact details

100 Corporate Ct
United States
+1 (908) 2227000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.04 billion
Shares in issue:
75.46 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Matthew Klein
    President, Chief Executive Officer, Director
  • Pierre Gravier
    Chief Financial Officer
  • Neil Almstead
    Chief Technical Operations Officer
  • Mark Boulding
    Executive Vice President, Chief Legal Officer
  • Christine Utter
    Senior Vice President, Chief Accounting Officer, Head - People Services
  • Eric Pauwels
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.